Bortezonib (velcade) is the first proteasome inhibitor that has entered clinical trial.
波替单抗(万珂)是第一个进入临床试验的蛋白酶体抑制剂。
Compared to traditional chemotherapy, what is the advantage of Velcade?
您认为含万珂的化疗方案与传统方案相比，有什么优势？
Reconstituted VELCADE should be administered within 8 hours of preparation.
重新配制的万珂应当在制备后8个小时内使用。
Reconstituted VELCADE should be administered within 8 hours of preparation.
重新配制的万珂应当在制备后8个小时内使用。
应用推荐